Edgewise Therapeutics (EWTX): Perceptive Advisors LLC added to its stake +3.86M shares
Perceptive Advisors LLC added to its stake in Edgewise Therapeutics, per its Q1 2025 13F.
- 6.55M
- Shares reported · +3.86M vs prior quarter
- 5.1%
- Disclosed portfolio weight
- $144M
- Reported value
- Holdings as of
- Mar 31, 2025
- Filed
- Aug 6, 2025
What stands out in this filing
- 2,685,537 shares in Q4 2024, 6,547,328 now (+143.8% in share count).
- Reported at $144M, 5.09% of the portfolio value in this 13F filing.
- 3 other tracked managers reported the same kind of change for Q1 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
- Aug 12, 2025Insider · 6 peopleInsiders: 6 sales (~$251K)
- Aug 26, 2025InsiderDirector sold ~$1.46M of EWTX shares in the open market
- Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 10, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 10, 2025, Edgewise Therapeutics, Inc. (the “ Company ”) announced the appointment of Michael Nofi as the Company’s Chief Financial Officer, effective November 10, 2025.”
- Nov 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 19, 2025, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Christopher Martin to serve as a Class I director, with a term expiring at the Company’s 2028 annual meeting of stockholders.”
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Edgewise Therapeutics
For Edgewise Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EWTX page.
How this filing works
Explore the data
Common questions
What does this filing report about Edgewise Therapeutics (EWTX) stock?
Perceptive Advisors LLC added to its stake in Edgewise Therapeutics, per its Q1 2025 13F. Now 6.55M shares, $144M reported value, 5.1% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Mar 31, 2025. Filed: Aug 6, 2025.
What stands out in this filing?
2,685,537 shares in Q4 2024, 6,547,328 now (+143.8% in share count). Reported at $144M, 5.09% of the portfolio value in this 13F filing. 3 other tracked managers reported the same kind of change for Q1 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Edgewise Therapeutics recently?
For Edgewise Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the EWTX page.
Does this mean EWTX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Edgewise Therapeutics
- SEC Form 4Nov 18, 2026
- SEC Form 144Nov 16, 2026
- SEC Form 4Nov 10, 2026
- SEC Schedule 13GNov 5, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its EWTX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
